Dupixent (dupilumab) is used to treat eczema that has not responded to topical medications. It’s approved for this use in adults and children ages 6 months and older. Some of Dupixent’s side effects ...
Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
“The impact of COPD extends far beyond the patient. Debilitating breathlessness and irreversible lung damage make it difficult for patients to do simple daily tasks, placing a significant burden on ...
Aiming to offer an advantage over Dupixent (dupilumab, Regeneron Pharmaceuticals Inc.), dermatology-focused Galderma Holding SA won clearance from the U.S. FDA for Nemluvio (nemolizumab) as a ...
Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results